Krystal Biotech logo

Krystal Biotech

KRYS | NASDAQ
Chart Builder DCF Calculator
$297.90
-$7.33 (-2.40%)
At close: Nov 16, 2026, 4:00 PM ET
$297.90
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.40%

Rating

Updated: Nov 14, 2026
65.1
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #88/1021 (Top 9%)

Key Statistics

Market Data

Market Cap $8.83B
1D Range
295.01 306.44
52W Range
204.10 378.15

Valuation (TTM)

PE 40.42
PB 6.15
EV/EBITDA 31.42

Valuation (NTM)

Forward PE 39.80
Forward PEG 2.91
Price Target $416.00
Loading financial charts...

Profile

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic...

Sector Healthcare
Industry Biotechnology
Employees 295
IPO Date Sep 20, 2017
Fiscal Year January - December

Latest News

Krystal Biotech Analyst Says Stock Weakness 'Overblown'

15 days ago · benzinga.com

Krystal Biotech Analyst Says Stock Weakness 'Overblown'
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript

15 days ago · seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

15 days ago · zacks.com

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
Krystal Biotech Q3 Earnings Call Highlights

15 days ago · marketbeat.com

Krystal Biotech Q3 Earnings Call Highlights
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results

15 days ago · globenewswire.com

Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

22 days ago · zacks.com

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

26 days ago · globenewswire.com

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

1 month ago · zacks.com

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

1 month ago · globenewswire.com

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

1 month ago · seekingalpha.com

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

Earnings

Latest Earnings
Nov 2, 2026
EPS
$2.05
Beat +14.53%
REV
$127.34M
Beat +1.25%
Next Earnings
Feb 16, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$416.00
Upside
+39.64%
Buy (10)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.